The Value of CE-LUS During Robot-assisted Surgery for Primary Colorectal Cancer (CE-LUS)
Colorectal Cancer
About this trial
This is an interventional diagnostic trial for Colorectal Cancer focused on measuring contrast enhanced laparoscopic ultrasound, CE-LUS, LUS, robot assisted CRC resection
Eligibility Criteria
Inclusion Criteria:
- patients scheduled to robot-assisted CRC resection
- patients with histologically verified cancer i colon or rectum
- informed consent
- patients with minimum age of 18
- patients without liver metastases
Exclusion Criteria:
- patients who have not given informed consent
- patients with severe heart disease, lung hypertension, or had had a heart attack < 7 days
- patients with alcohol or drug abuse.
- patients with liver metastases
Sites / Locations
- Odense University Hospital
Arms of the Study
Arm 1
Experimental
CE-LUS
Laparoscopic ultrasound examination (LUS) of the liver during robot assisted CRC surgery. The liver is systematically scanned for unrecognized liver metastases. After the laparoscopic LUS procedure, the liver is then systematically scanned with contrast enhancement with SonoVue® containing Sulphurhexafluoride. A bolus of 2.5 ml is injected into a peripheral vein followed by 10 ml of isotonic saline. The liver is then systematically scanned in 3 phases (arterial, venous and parenchymatous phase) searching for unrecognized liver metastases. The procedure is repeated after 5 minutes. The time it takes to do the scan is measured and any technical challenges are reported. Time, challenges and findings of liver metastases (number, segment and size) are entered on a registration form.